tradingkey.logo
tradingkey.logo
Search

Zenas Biopharma Announces First Subject Dosed In Phase 1 Clinical Trial Of Zb021, A Novel, Potentially Best-In-Class Oral Il-17Aa/Af Inhibitor

ReutersMay 13, 2026 10:53 AM
facebooktwitterlinkedin
View all comments0

Zenas Biopharma Inc ZBIO.O:

  • ZENAS BIOPHARMA ANNOUNCES FIRST SUBJECT DOSED IN PHASE 1 CLINICAL TRIAL OF ZB021, A NOVEL, POTENTIALLY BEST-IN-CLASS ORAL IL-17AA/AF INHIBITOR

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

Tradingkey
KeyAI